Regression and Classification of Alzheimer’s Disease Diagnosis Using NMF-TDNet Features From 3D Brain MR Image

Because of headways in deep learning and clinical imaging innovation, a few specialists are presently utilizing convolutional neural networks (CNNs) to extricate profound level properties from clinical pictures to all the more exactly classify Alzheimer's disease (AD) and expect clinical scores. A limited scale profound learning network called PCANet utilizes principal component analysis (PCA) to make multi-facet channel banks for the incorporated learning of information. Blockwise histograms are made after binarization to get picture ascribes. PCANet is less versatile than different frameworks since the multi-facet channel banks are made involving test information and the produced highlights have aspects during the many thousands or even many thousands. To conquer these issues, we present in this study a PCANet-based, information free organization called the nonnegative matrix factorization tensor decomposition network (NMF-TDNet). To deliver the last picture highlights, we first form higher-request tensors and utilize tensor decomposition (TD) to achieve information dimensionality decrease. Specifically, we foster staggered channel banks for test getting the hang of utilizing nonnegative matrix factorization(NMF) as opposed to PCA. These properties serve as input to the support vector machine (SVM) that our technique employs to diagnose AD, forecast clinical score, and categorise AD

Hybrid Approach for Alzheimer’s Disease Diagnosis For 3D Brain MR Image

Because of headways in deep learning and clinical imaging innovation, a few specialists are presently utilizing convolutional neural networks (CNNs) to extricate profound level properties from clinical pictures to all the more exactly classify Alzheimer's disease (AD) and expect clinical scores. A limited scale profound learning network called PCANet utilizes principal component analysis (PCA) to make multi-facet channel banks for the incorporated learning of information. Blockwise histograms are made after binarization to get picture ascribes. PCANet is less versatile than different frameworks since the multi-facet channel banks are made involving test information and the produced highlights have aspects during the many thousands or even many thousands. To conquer these issues, we present in this study a PCANet-based, information free organization called the nonnegative matrix factorization tensor decomposition network (NMF-TDNet). To deliver the last picture highlights, we first form higher-request tensors and utilize tensor decomposition (TD) to achieve information dimensionality decrease. Specifically, we foster staggered channel banks for test getting the hang of utilizing nonnegative matrix factorization(NMF) as opposed to PCA. These properties serve as input to the support vector machine (SVM) that our technique employs to diagnose AD, forecast clinical score, and categorise AD

TCSC-STATCOM Controller for the Voltage Stability Improvement of the Wind Farm Connected to the Grid

The project is about the improvement of voltage stability of the system which has a wind farm connected to the Grid. A combination of TCSC and STATCOM is used in the controller. The controller ensures that the system receives enough reactive power to maintain stability. The simulation model is going to be inbuilt MATLAB/SIMULINK. output voltages of the system without the controller, with each component acting separately and the collaborative control effect of TCSC and STATCOM, will be compared and studied in the simulated model to prove the efficiency of the controller

Liraglutide and Renal Outcomes in Type 2 Diabetes.

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .)